RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis (Q35578252)

9 August 2017

title

RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis (English)

1 reference

9 August 2017

1 reference

Ellen V Stevens

1

1 reference

9 August 2017

Natalie Banet

2

1 reference

9 August 2017

Cercina Onesto

3

1 reference

9 August 2017

Ana Plachco

4

1 reference

9 August 2017

Jamie K Alan

5

1 reference

9 August 2017

Nana Nikolaishvili-Feinberg

6

1 reference

9 August 2017

Bentley R Midkiff

7

1 reference

9 August 2017

Pei Fen Kuan

8

1 reference

9 August 2017

Jinsong Liu

9

1 reference

9 August 2017

C Ryan Miller

10

1 reference

9 August 2017

Dominico Vigil

11

1 reference

9 August 2017

Lee M Graves

12

1 reference

9 August 2017

Channing J Der

13

1 reference

9 August 2017

publication date

1 July 2011

1 reference

9 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Small GTPases (journal)

1 reference

9 August 2017

volume

2

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

202-210

1 reference

Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

RhoGDI signaling provides targets for cancer therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

RhoGDI2 as a therapeutic target in cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Rho GTPase function in tumorigenesis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

The cytoskeleton and cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Rho GTPases in cancer cell biology

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Assay of Rab25 function in ovarian and breast cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

GDIs: central regulatory molecules in Rho GTPase activation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

A genetically defined model for human ovarian cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Changes in gene expression during progression of ovarian carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

LyGDI is a promising biomarker for ovarian cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225909

Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22145092

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22145092

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/SGTP.2.4.17795

1 reference

9 August 2017

1 reference

9 August 2017

1 reference